NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sanders GD, Lowenstern A, Borre E, et al. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Oct. (Comparative Effectiveness Reviews, No. 214.)

Acronyms and Abbreviations

AcronymDefinition
ABCAge, biomarkers, clinical history
ACCAmerican College of Cardiology
ACTIVE-AEffect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation (trial)
ACTIVE-WAtrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (trial)
ACPAmplatzer cardiac plug
ACTSAnti-Clot Treatment Scale
AFAtrial fibrillation
AHAAmerican Heart Association
AHRQAgency for Healthcare Research and Quality
AMADAEUSEvaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (trial)
ApoEApolipoprotein E
ARISTOTLEApixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (trial)
ASAAcetylsalicylic acid
ASDAtrial septal defect
ATRIAAge, female, diabetes, congestive heart failure, hypertension, proteinuria
AVAortic valve
AVERROESApixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (trial)
BAFTABirmingham Atrial Fibrillation Treatment of the Aged Study
BRIBleeding risk index
CABGCoronary artery bypass grafting
CADCoronary artery disease
CDSRCochrane Database of Systematic Reviews
CERComparative effectiveness research/review
CHADS2Congestive heart failure, hypertension, age >75, diabetes, stroke/TIA (2 points)
CHA2DS2-VAScCongestive heart failure/left ventricular ejection fraction ≤40%, hypertension, age ≥75 (2 points), diabetes, stroke/TIA/thromboembolism (2 points), vascular disease, age 65-74, sex
CIConfidence interval
CKDChronic kidney disease
CKD-EPIChronic Kidney Disease Epidemiology Collaboration
CNSCentral nervous system
COPDChronic obstructive pulmonary disease
CQContextual question
CrClCreatinine clearance
CTComputed tomography
cTnT-hsHigh-sensitivity cardiac troponin T
DMDiabetes mellitus
DOACDirect oral anticoagulant
DSMBData safety and monitoring board
DTIDirect thrombin inhibitor
DVTDeep vein thrombosis
eGFREstimated glomerular filtration rate
EHCEffective Healthcare
ENGAGE-AFEffective Anticoagulation with Factor Xa Next Generation in Atrial
TIMI-48Fibrillation–Thrombolysis in Myocardial Infarction 48 (trial)
EPCEvidence-based Practice Center
eQ-5D-3LEuroQol 5 dimensions questionnaire, level 3 version
EREmergency room
ESRDEnd-stage renal disease
FASTRHACThromboembolic and Bleeding Risk Stratification in Patients With Nonvalvular Atrial Fibrillation
GDF-15Growth differentiation factor 15
GIGastrointestinal
HAESTHeparin in Acute Embolic Stroke Trial
HAS-BLEDHypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (> 65), drugs/alcohol concomitantly
HEMORR2HAGESHepatic or renal disease, ethanol (alcohol) abuse, malignancy, older (> 75), reduced platelet count or function, rebleeding risk (2 points), hypertension (uncontrolled), anemia, genetic factors, excessive fall risk, stroke history
HFHeart failure
HFpEFHeart Failure with a Preserved Ejection Fraction
HIVHuman immunodeficiency virus
HRHazard ratio
HRQOLHealth-related quality of life
HTNHypertension
INRInternational normalized ratio
IQRInterquartile ratio
IRRInterrater reliability
ISTHInternational Society on Thrombosis and Haemostasis
ITTIntention to treat
KQKey Question
LAALeft atrial appendage
LAACLeft atrial appendage closure
LVLeft ventricular
LVEFLeft ventricular ejection fraction
LVHLeft ventricular hypertrophy
LVSLeft ventricular systolic
LVSDLeft ventricular systolic dysfunction
mgMilligram
MIMyocardial infarction
mL/minMilliliter per minute
MMSEMini-Mental State Examination
MRMitral regurgitation
MRIMagnetic resonance imaging
MVMitral valve
NDANondedicated Amplatzer
NMCRNon-major clinically relevant
NNTNumber needed to treat
NRNot reported
NVAFNonvalvular atrial fibrillation
NYHANew York Heart Association
OACOral anticoagulant
OROdds ratio
PADPeripheral artery disease
PCIPercutaneous coronary intervention
PCORIPatient-Centered Outcomes Research Institute
PEPulmonary embolism
PICOTSPopulations, Interventions, Comparators, Outcomes, Timing, Settings
PFOPatent foramen ovale
PLAATOPercutaneous Left Atrial Appendage Transcatheter Occlusion
PREVAILWatchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy (trial)
PROTECT-AFWatchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (trial)
QOLQuality of life
QUADAS-2Quality Assessment of Diagnostic Accuracy Studies-2
RCTRandomized controlled trial
RE-LYRandomized Evaluation of Long-Term Anticoagulation Therapy (trial)
ROBRisk of bias
ROCKET-AFRivaroxaban Once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation
RRRelative risk
SAT-QSatisfaction Questionnaire
SDStandard deviation
SEStandard error
SECSpontaneous echocardiographic contrast
SEESystemic embolic event
SOEStrength of evidence
SRSystematic review
SRFStable renal function
TEThromboembolic
TEETransesophageal echocardiography
TIATransient ischemic attack
TnCTroponin C
TnITroponin I
TnTTroponin T
TTETransthoracic echocardiography
TTE-LAWVTransthoracic echocardiographic LAA wall velocity
TTRTime in therapeutic range
VKAVitamin K antagonist
VSDVentricular septal defect
WRFWorsening renal function